Literature DB >> 34417711

Molecular description of meningeal solitary fibrous tumors/hemangiopericytomas compared to meningiomas: two completely separate entities.

Michel Kalamarides1,2,3, Gaëlle Pierron4, Caroline Apra5,6,7, Delphine Guillemot4, Eléonore Frouin4, Corinne Bouvier8, Karima Mokhtari2,3,9.   

Abstract

INTRODUCTION: Meningeal solitary fibrous tumors (SFT), like all SFT, are defined by NAB2-STAT6 fusion and share clinicopathologic similarities with meningiomas, the most frequent meningeal tumors. Our aim is to establish the molecular identity of meningeal SFT and seek molecular prognostic factors.
METHODS: RNA sequencing and whole exome sequencing were performed in STAT6-positive SFT and grade 2-3 meningiomas, and data concerning other soft tissues tumors was obtained from the local database. Uniform manifold approximation and projection, individual gene expression and Gene Set Enrichment Analysis were performed.
RESULTS: RNA clustering shows that SFT share a common molecular signature, different from any other type of tumoral tissue. Meningeal SFT aggregate with other SFT, with no clinical or histological subgroup. Comparison of genes expressions suggests significant over-expressions of ZIC2, ZIC3, ZIC5, GABBR2, TP53 in CNS-SFT. The pathogenic TP53 c.743G>T variant, previously undescribed in SFT, was found in one sample of meningeal SFT during malignant progression.
CONCLUSIONS: Meningeal SFT are molecular counterparts of extra-meningeal SFT, completely separate from meningiomas. They might develop from the same tissues and benefit from the same treatments as SFT.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Hemangiopericytoma; Meninges; Meningioma; NAB2–STAT6; Solitary fibrous tumor; TP53

Mesh:

Substances:

Year:  2021        PMID: 34417711     DOI: 10.1007/s11060-021-03830-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  29 in total

Review 1.  Analysis of NAB2-STAT6 Gene Fusion in 17 Cases of Meningeal Solitary Fibrous Tumor/Hemangiopericytoma: Review of the Literature.

Authors:  Sayaka Yuzawa; Hiroshi Nishihara; Lei Wang; Masumi Tsuda; Taichi Kimura; Mishie Tanino; Shinya Tanaka
Journal:  Am J Surg Pathol       Date:  2016-08       Impact factor: 6.394

2.  Comparison of published risk models for prediction of outcome in patients with extrameningeal solitary fibrous tumour.

Authors:  Elizabeth G Demicco; Anthony M Griffin; Rebecca A Gladdy; Brendan C Dickson; Peter C Ferguson; Carol J Swallow; Jay S Wunder; Wei-Lien Wang
Journal:  Histopathology       Date:  2019-09-05       Impact factor: 5.087

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Prostaglandin D synthase (beta-trace) in meningeal hemangiopericytoma.

Authors:  M Kawashima; S O Suzuki; T Yamashima; M Fukui; T Iwaki
Journal:  Mod Pathol       Date:  2001-03       Impact factor: 7.842

5.  Solitary fibrous tumors and hemangiopericytomas of the meninges: overlapping pathological features and common prognostic factors suggest the same spectrum of tumors.

Authors:  Corinne Bouvier; Philippe Métellus; André Maues de Paula; Alexandre Vasiljevic; Anne Jouvet; Jacques Guyotat; Karima Mokhtari; Pascale Varlet; Henry Dufour; Dominique Figarella-Branger
Journal:  Brain Pathol       Date:  2011-12-22       Impact factor: 6.508

6.  Intracranial solitary fibrous tumors/hemangiopericytomas: first report of malignant progression.

Authors:  Caroline Apra; Karima Mokhtari; Philippe Cornu; Matthieu Peyre; Michel Kalamarides
Journal:  J Neurosurg       Date:  2017-06-23       Impact factor: 5.115

7.  Primary intracranial haemangiopericytoma: comparison of survival outcomes and metastatic potential in WHO grade II and III variants.

Authors:  Omprakash Damodaran; Peter Robbins; Neville Knuckey; Michael Bynevelt; George Wong; Gabriel Lee
Journal:  J Clin Neurosci       Date:  2014-04-13       Impact factor: 1.961

8.  Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein.

Authors:  Leonille Schweizer; Christian Koelsche; Felix Sahm; Rosario M Piro; David Capper; David E Reuss; Stefan Pusch; Antje Habel; Jochen Meyer; Tanja Göck; David T W Jones; Christian Mawrin; Jens Schittenhelm; Albert Becker; Stephanie Heim; Matthias Simon; Christel Herold-Mende; Gunhild Mechtersheimer; Werner Paulus; Rainer König; Otmar D Wiestler; Stefan M Pfister; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2013-04-11       Impact factor: 17.088

9.  Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing.

Authors:  Dan R Robinson; Yi-Mi Wu; Shanker Kalyana-Sundaram; Xuhong Cao; Robert J Lonigro; Yun-Shao Sung; Chun-Liang Chen; Lei Zhang; Rui Wang; Fengyun Su; Matthew K Iyer; Sameek Roychowdhury; Javed Siddiqui; Kenneth J Pienta; Lakshmi P Kunju; Moshe Talpaz; Juan Miguel Mosquera; Samuel Singer; Scott M Schuetze; Cristina R Antonescu; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2013-01-13       Impact factor: 38.330

10.  PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss.

Authors:  Matthieu Peyre; Céline Salaud; Estelle Clermont-Taranchon; Michiko Niwa-Kawakita; Stephane Goutagny; Christian Mawrin; Marco Giovannini; Michel Kalamarides
Journal:  Oncotarget       Date:  2015-10-20
View more
  1 in total

Review 1.  Spinal Solitary Fibrous Tumors: An Original Multicenter Series and Systematic Review of Presentation, Management, and Prognosis.

Authors:  Caroline Apra; Amira El Arbi; Anne-Sophie Montero; Fabrice Parker; Steven Knafo
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.